Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1696467

registered interest
date	15/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Arthritis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to raise awareness of the (a) symptoms of inflammatory arthritis and (b) support available for patients and families.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	18888
answer	answer is ministerial correction date of answer 20/03/2024 answer text <p>The Government has produced a guide on musculoskeletal (MSK) conditions, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/musculoskeletal-health-applying-all-our-health/musculoskeletal-health-applying-all-our-health" target="_blank">https://www.gov.uk/government/publications/musculoskeletal-health-applying-all-our-health/musculoskeletal-health-applying-all-our-health</a></p><p>The Department is currently developing a Major Conditions Strategy, in consultation with NHS England and colleagues across the Government. Given their contribution to the burden of disease, MSK conditions such as arthritis will be included in the strategy.</p><p>The National Institute for Health and Care Excellence (NICE) has produced expert guidance to support healthcare professionals in the early diagnosis and management of rheumatoid arthritis and osteoarthritis. The guidance for the early diagnosis and management of rheumatoid arthritis and osteoarthritis is available, respectively, at the following links:</p><p><a href="https://www.nice.org.uk/guidance/ng100" target="_blank">https://www.nice.org.uk/guidance/ng100</a></p><p><a href="https://www.nice.org.uk/guidance/ng226" target="_blank">https://www.nice.org.uk/guidance/ng226</a></p><p>From 2022/23 to 2024/25, the Government is spending more than £11.3 billion to support elective recovery and tackle long waiting times, which could deliver nine million more checks and procedures to help support patients with conditions like arthritis. In the Spring Budget 2023, the Government also announced £400 million of funding for scaling up MSK Physical Activity Hubs and embedding employment advice within MSK pathways.</p><p>General rheumatology services, which support people with a range of conditions, including rheumatoid arthritis and osteoarthritis, are locally commissioned by integrated care boards, which are best placed to make decisions according to local need.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 20/03/2024 10:02:48 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4385 label Biography information for Dr Philippa Whitford

1696166

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to take steps to help increase productivity in the Medicines and Healthcare products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18748
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18749 18750 18751 18752 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696174

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the capacity of the Medicines and Healthcare products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18749
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18748 18750 18751 18752 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696185

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has received representations from the scientific community on the efficiency of the Medicines and Healthcare products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18750
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18748 18749 18751 18752 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696188

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the adequacy of funding provided to the Medicines and Healthcare products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18751
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18748 18749 18750 18752 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696190

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to (a) monitor and (b) report on the performance of the Medicines and Healthcare Products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18752
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18748 18749 18750 18751 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696191

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will (a) make an assessment of the effectiveness of clinical research practices in Singapore and (b) use that assessment to improve clinical research in the UK.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18753
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>As leaders in research, science and innovation, the United Kingdom works closely with Singapore across priorities that will drive economic growth and positive societal impact. Our Prime Ministers issued a Joint Declaration on the Singapore-United Kingdom Strategic Partnership in September 2023, which includes research, science, innovation, and technology as one of five priority pillars for the partnership. We will continue to identify opportunities to learn from countries around the world, including Singapore.</p><p>We are focussed on improving clinical research in the UK based on barriers and enablers that have been identified through multiple fora and stakeholders. The vision for the Future of Clinical Research Delivery and the Government response to the O’Shaughnessy review set out our plans to speed up clinical trials, and make it easier for revolutionary healthcare treatments to get to National Health Service patients through research.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/03/2024 17:56:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696215

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Electronic Cigarettes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate she has made (a) of the number of vaping products that have been seized by trading standards and (b) of those, the number that (i) were non-compliant with UK regulations and (ii) have gone through the Medicines and Healthcare products Regulatory Agency notification process.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	18760
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The underage and illicit sale of tobacco, and more recently vapes, undermines the work the Government is doing to regulate the industry and protect public health. The Government is increasing investment for our enforcement agencies by £30 million per year. In addition, the Government also announced £3 million of investment to a new illicit vapes enforcement unit, led by National Trading Standards, building on existing work by trading standards officers across the country. They identified that 2.1 million illicit vapes were seized across England by trading standards in 2022 to 2023. These vapes often contain unknown ingredients, higher levels of nicotine, and are often made easily available through markets that target children. The Department does not hold data on the total number of vaping products seized by Trading Standards that have successfully gone through the Medicines and Healthcare products Regulatory Agency’s notification process.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 19/03/2024 17:03:09 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4603 label Biography information for Preet Kaur Gill

1696229

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Streptococcus: Babies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the adequacy of reporting the incidence of Group B streptococcal infections in newborns.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	18687
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>No specific assessment has been made.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 19/03/2024 16:20:53 answering member 4492 label Biography information for Maria Caulfield
tabling member	1604 label Biography information for Mr Virendra Sharma

1696230

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Streptococcus: Babies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department has made an estimate of the annual economic costs to the NHS of Group B streptococcus infections in newborns.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	18688
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>No specific assessment has been made.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 19/03/2024 16:26:08 answering member 4492 label Biography information for Maria Caulfield
tabling member	1604 label Biography information for Mr Virendra Sharma